LIMN (Liminatus Pharma) Interest Coverage: 0 (At Loss) (As of Mar. 2026)


What is Liminatus Pharma Interest Coverage?

Liminatus Pharma LIMN +9.99% Interest Coverage is 0 (At Loss) as of Mar. 2026. The stock has 1 warning sign investors should review. Among 377 Biotechnology companies, Liminatus Pharma ranks worse than 265251.72% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Liminatus Pharma's Operating Income for the three months ended in Mar. 2026 was $-1.10 Mil. Liminatus Pharma's Interest Expense for the three months ended in Mar. 2026 was $-0.02 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Liminatus Pharma's Interest Coverage or its related term are showing as below:


LIMN's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Liminatus Pharma  (NAS:LIMN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Liminatus Pharma Interest Coverage Related Terms

Liminatus Pharma Interest Coverage Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Liminatus Pharma Interest Coverage Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Interest Coverage
0.00 0.00 0.00 0.00

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LIMN vs XBIO, PCSA, SILO: Interest Coverage Comparison

For the Biotechnology subindustry, Liminatus Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liminatus Pharma Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liminatus Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Liminatus Pharma's Interest Coverage falls into.


Liminatus Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Liminatus Pharma's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Liminatus Pharma's Interest Expense was $-0.22 Mil. Its Operating Income was $-2.97 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Liminatus Pharma did not have earnings to cover the interest expense.

Liminatus Pharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Liminatus Pharma's Interest Expense was $-0.02 Mil. Its Operating Income was $-1.10 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Liminatus Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Liminatus Pharma (LIMN) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Liminatus Pharma and its competitors. According to the industry distribution chart, Liminatus Pharma ranks #999999 out of 377 companies in the Biotechnology industry.
Is Liminatus Pharma's Interest Coverage too high?
Liminatus Pharma's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Liminatus Pharma ranks #999999 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Liminatus Pharma's Interest Coverage compare to XBIO and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #999999 out of 377 companies for Interest Coverage. This places Liminatus Pharma in the lower half of its industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Liminatus Pharma and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liminatus Pharma's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.